帕博利珠单抗治疗乳腺癌时代乳房再造的重建难题:病例系列综述
本文综述帕博利珠单抗等免疫治疗相关不良事件,并报告5例接受帕博利珠单抗治疗后行乳房再造的患者出现甲状腺功能异常、心力衰竭及表皮松解等意外并发症。文章指出,随着免疫治疗在乳腺癌中应用增加,需理解其不良事件对手术结局的影响以优化再造患者管理。
要点
- 帕博利珠单抗等免疫治疗可致甲状腺功能异常、心力衰竭、表皮松解等不良事件。
- 这些不良事件可能影响乳房再造的围手术期和术后结局。
- 乳腺癌再造术前需评估免疫治疗相关不良事件风险。
核心结论
- 帕博利珠单抗等免疫治疗相关不良事件可能影响乳房再造的手术结局,需引起重视。
研究设计与样本
- 病例系列综述,报告5例接受帕博利珠单抗治疗后行乳房再造的患者。
主要发现
- 5例患者术后出现甲状腺功能异常、心力衰竭及表皮松解等意外并发症。
临床怎么用
- 对接受帕博利珠单抗等免疫治疗的乳腺癌患者,再造术前应评估免疫相关不良事件风险。
局限性
- 病例系列样本量小,关于帕博利珠单抗对围手术期及术后结局影响的信息仍缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pembrolizumab, commercially known as Keytruda, is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1). Its popularity increased after the KEYNOTE-522 trial demonstrated a statistically significant increase in pathologic complete response compared to placebo in early-stage triple-negative breast cancer patients. This led to global regulatory approvals and a subsequent surge in clinical utilization. Despite the positive outcomes in clinical trials, there is a paucity of information concerning its influence on perioperative and postoperative outcomes, particularly during breast reconstruction. This manuscript offers a concise review of adverse events linked to pembrolizumab and similar immunotherapies. We detail a case series of five patients post-pembrolizumab treatment who underwent breast reconstruction and encountered unforeseen complications, such as thyroid dysregulation, cardiac failure, and epidermolysis. Given the increased use of immunotherapies in breast cancer care, understanding the impact of these adverse effects on surgical outcomes is crucial for optimizing patient care in breast cancer reconstruction.
引用
- Zhu L, Khong J, Heron MJ, et al. Reconstructive conundrums in the era of pembrolizumab treatment for breast cancer: A case series review. J Plast Reconstr Aesthet Surg. 2026. PMID: 42314326. doi:10.1016/j.bjps.2026.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。